SCHEMBL1268959

SCHEMBL1268959

O=C(c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ncc1Sc1ccc(S(=O)(=O)N2CCCCC2)cc1)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ TDP1 Q9NUW8 1/20 0.40
▸ LMNA P02545 5/20 0.39
▸ HTT P42858 3/20 0.39
▸ TSHR P16473 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ GAA P10253 2/20 0.38
▸ MAPT P10636 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NAMPT P43490 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1268887 0.90 ALDH1A1 (0.46) ALDH1A1KDM4EMEN1KMT2ATDP1
SCHEMBL1268585 0.86 ALDH1A1 (0.42) ALDH1A1KDM4EMEN1KMT2ATDP1
SCHEMBL5226632 0.85 CNR1 (0.43) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL1269665 0.85 HTT (0.40) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL1269568 0.85 ALDH1A1 (0.41) ALDH1A1KDM4EMEN1KMT2ATDP1
SCHEMBL1269493 0.84 HTT (0.38) ALDH1A1KDM4EMEN1KMT2ATDP1
SCHEMBL1269009 0.83 ALDH1A1 (0.39) ALDH1A1KDM4EMEN1KMT2ATDP1
SCHEMBL1269400 0.83 ALDH1A1 (0.47) ALDH1A1KDM4EMEN1KMT2ATDP1
SCHEMBL1269603 0.83 GAA (0.45) ALDH1A1KDM4ELMNAHTTGAA
SCHEMBL1269470 0.83 ALDH1A1 (0.40) ALDH1A1KDM4EMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG ALDH1A1 2237/4885KDM4E 2907/4885MEN1 4841/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG ALDH1A1 2237/4885KDM4E 2907/4885MEN1 4841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback